Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06607549 · ClinicalTrials.gov registry record · Phase 1
Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)
A Phase 1 study of Central Nervous System Lymphoma, sponsored by University of Utah.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT06607549 is a Phase 1 study of Central Nervous System Lymphoma that is actively recruiting participants, run by University of Utah. The registered enrollment target is 12 participants, below the 105-participant average among 14 other Central Nervous System Lymphoma trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06607549, a Phase 1 study of Central Nervous System Lymphoma, is actively recruiting participants, sponsored by University of Utah.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this clinical trial is to learn if drugs loncastuximab tesirine and rituximab (lonca-R) after stereotactic radiosurgery are safe and effective for treatment of central nervous system lymphomas.
Conditions Studied
Interventions
- DRUG Loncastuximab tesirine and rituximab (Lonca-R)
Study Locations (1)
Utah
- Huntsman Cancer Institute at University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-03-18 |
| Est. Completion | 2030-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06607549
The ClinicalTrials.gov registry entry for NCT06607549 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 105-participant average among 14 other Central Nervous System Lymphoma trials with a reported enrollment target (89% lower). The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Central Nervous System Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Loncastuximab tesirine and rituximab (Lonca-R) is the first listed.
NCT06607549 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT06607549 about?
NCT06607549 is a clinical study titled "Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)". The purpose of this clinical trial is to learn if drugs loncastuximab tesirine and rituximab (lonca-R) after stereotactic radiosurgery are safe and effective for treatment of central nervous system lymphomas.
What is the current status of trial NCT06607549?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2025-03-18. Estimated completion is 2030-11.
What conditions does trial NCT06607549 study?
This clinical trial studies the following conditions: Central Nervous System Lymphoma.
What interventions are being tested in trial NCT06607549?
The interventions under investigation include: Loncastuximab tesirine and rituximab (Lonca-R) (DRUG).
Who is sponsoring clinical trial NCT06607549?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06607549 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Central Nervous System Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma
RECRUITING · Phase 1
-
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
RECRUITING · Phase 1
-
Acalabrutinib in CNSL
ACTIVE NOT RECRUITING · Phase 1
-
Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed)
COMPLETED · Phase 1
-
DALY II USA/ MB-CART2019.1 for DLBCL
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.